Neuro

BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona

Retrieved on: 
Friday, December 2, 2022

Dr. Aguilar-Valles will present preclinical data supporting the acute and long-term anti-depressant activity of BETR-001 monotherapy in animal models.

Key Points: 
  • Dr. Aguilar-Valles will present preclinical data supporting the acute and long-term anti-depressant activity of BETR-001 monotherapy in animal models.
  • Furthermore, the data shows that BETR-001 promotes structural neuroplasticity in brain neurons and this effect is partly mediated by the activation of 5-HT2A receptor.
  • BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and other respiratory viral infections.
  • The department has an interdisciplinary approach to understanding the emergence, prevention and treatment of mental and physical disorders.

GlassView To Enhance Marketing Performance with Investment in Cogwear's Emotion-Sensing Headband

Retrieved on: 
Thursday, December 1, 2022

NEW YORK, Dec. 1, 2022 /PRNewswire/ -- GlassView, the world's largest independent video advertising distribution and performance platform, is making a strategic investment in brain health startup Cogwear to advance a new neuromarketing headband. The patent-pending device, designed to look and feel like a comfortable athletic headband, senses emotions and other physiological feedback directly from the brain in real time. It can gauge audience affinity for products and brands shown in digital video advertisements, so that advertisers can optimize creative content.

Key Points: 
  • NEW YORK, Dec. 1, 2022 /PRNewswire/ -- GlassView , the world's largest independent video advertising distribution and performance platform, is making a strategic investment in brain health startup Cogwear to advance a new neuromarketing headband.
  • As part of the agreement, GlassView will outfit thousands of volunteers with 5,000 of Cogwear's patented headbands in the coming 12-36 months.
  • GlassView expects to acquire tens of millions of anonymized data points during the initial roll out in the US.
  • Through emotion-based targeting and optimization, high frequency trading (SmartGamma) and delivery across connected devices, GlassView is best known for its performance.

Curebase Partners with Redenlab to Expand Data Capture Capabilities in Pharma Trials

Retrieved on: 
Thursday, December 1, 2022

Redenlab, a neuroscience technology company, uses speech and language biometrics to enhance decision-making in clinical trials.

Key Points: 
  • Redenlab, a neuroscience technology company, uses speech and language biometrics to enhance decision-making in clinical trials.
  • "We service in-clinic, in-home or virtual trials with speech software and hardware solutions capable of meeting regulatory requirements for security and integrity of data in clinical trials."
  • Curebase can utilize these capabilities where applicable in pharma and neuro trials to collect crucial metrics in a decentralized study model.
  • Partnerships like these enable sponsors to collect comprehensive and relevant data metrics in accordance with regulatory requirements for necessary trials.

MindLax Sleeping Mat With Vibroacoustic Technology Gently Massages With Sound for Instant Relaxation and Better Sleep

Retrieved on: 
Wednesday, November 30, 2022

With sound waves and guided sleep assistance, MindLax provides instant full-body relaxation that helps users fall asleep faster, sleep deeper, and wake up feeling better.

Key Points: 
  • With sound waves and guided sleep assistance, MindLax provides instant full-body relaxation that helps users fall asleep faster, sleep deeper, and wake up feeling better.
  • With Vibroacoustic Technology, MindLax Sleeping Mat transforms these sounds into a sound wave-like massage, creating a resonant effect to influence the neuro system naturally.
  • MindLax Sleeping Mat not only helps people to fall asleep easily but also to wake up feeling totally refreshed.
  • Powered by sound waves and the soothing sounds of nature, MindLax Sleeping Mat is the perfect solution for full-body relaxation and better sleep.

Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders

Retrieved on: 
Tuesday, November 22, 2022

Sonlicromanol, Khondrions wholly-owned lead asset, is being investigated in the Phase IIb programme in adult patients with MELAS spectrum disorders as genetically confirmed by the m.3243A>G mutation in the mitochondrial DNA.

Key Points: 
  • Sonlicromanol, Khondrions wholly-owned lead asset, is being investigated in the Phase IIb programme in adult patients with MELAS spectrum disorders as genetically confirmed by the m.3243A>G mutation in the mitochondrial DNA.
  • In line with previous studies, sonlicromanol was found to be safe and well tolerated in the Phase IIb programme, with no serious adverse effects.
  • These longer-term patient data are, therefore, instrumental in providing valuable insights for the design of the upcoming Phase III trial.
  • One of the most advanced disease-modifying drug candidates for mitochondrial disease in development, sonlicromanol has recently completed a Phase IIb study in adult patients with m.3243A>G MELAS spectrum disorders.

Khondrion announces sonlicromanol Phase IIb progress supporting Phase III development in MELAS spectrum disorders

Retrieved on: 
Tuesday, November 22, 2022

Sonlicromanol, Khondrions wholly-owned lead asset, is being investigated in the Phase IIb programme in adult patients with MELAS spectrum disorders as genetically confirmed by the m.3243A>G mutation in the mitochondrial DNA.

Key Points: 
  • Sonlicromanol, Khondrions wholly-owned lead asset, is being investigated in the Phase IIb programme in adult patients with MELAS spectrum disorders as genetically confirmed by the m.3243A>G mutation in the mitochondrial DNA.
  • In line with previous studies, sonlicromanol was found to be safe and well tolerated in the Phase IIb programme, with no serious adverse effects.
  • These longer-term patient data are, therefore, instrumental in providing valuable insights for the design of the upcoming Phase III trial.
  • One of the most advanced disease-modifying drug candidates for mitochondrial disease in development, sonlicromanol has recently completed a Phase IIb study in adult patients with m.3243A>G MELAS spectrum disorders.

20th Annual “Gathering for Cure” Awards Gala of World Brain Mapping Foundation to recognize Pioneering Innovation, Technology, Policy, Humanitarian and Philanthropic work

Retrieved on: 
Monday, November 21, 2022

LOS ANGELES, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Ticket registration is now open for the World Brain Mapping Foundation’s (WBMF) 20th Annual “Gathering for Cure” Awards Gala, taking place on Friday, February 17th, 2023, at the InterContinental Hotel in downtown Los Angeles. The Gala includes a cocktail/red carpet reception from 6-8pm, followed by a black-tie award banquet from 8-11pm and is part of the Annual World Congress of the Society for Brain Mapping and Therapeutics (SBMT), SBMT 2023 takes place from February 16th-19th at the Los Angeles Convention Center.

Key Points: 
  • The Gala is the Oscars of Neuroscience, says SBMT founder and WBMF President Dr. Babak Kateb .
  • Distinguished guests and past years awardees Dr. Deepak Chopra and Mr. Montel Williams are amongst celebrities who will be attending.
  • Oscar and Golden Globe award recipient actress Goldie Hawn will attend and receive the 2023 Beacon of Courage and Dedication award.
  • The Philips Healthcare Foundation will receive the 2023 Humanitarian award for its work in Ukraine.

OneStep Launches Industry-First Upper Body Range of Motion Capabilities

Retrieved on: 
Thursday, November 17, 2022

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- OneStep , an innovative platform for digital physical therapy using pioneering science that turns any smartphone into a clinical-grade motion analysis lab, announced today its capabilities are expanding to monitor the upper body.

Key Points: 
  • NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- OneStep , an innovative platform for digital physical therapy using pioneering science that turns any smartphone into a clinical-grade motion analysis lab, announced today its capabilities are expanding to monitor the upper body.
  • The cell phone is easily used to capture upper extremity range of motion as well, for instance by holding the phone and moving the arm.
  • OneStep has expanded its technology to include upper body capabilities and help an even greater number of patients to recover and overcome their injuries, and move in a healthier way.
  • OneStep will now measure range of motion in patients with common upper extremity related conditions such as rotator cuff injuries, chronic neck pain and other neuro-musculoskeletal conditions.

Brainomix announces new partnership with Pixyl to expand its offering with multiple sclerosis solution

Retrieved on: 
Friday, November 25, 2022

OXFORD, England, Nov. 25, 2022 /PRNewswire/ -- Brainomix, an AI-powered medtech solutions company, has announced a new partnership with Pixyl, an award-winning, Grenoble-based medtech specializing in medical neurology imaging. As part of the collaboration, Brainomix will distribute Pixyl's Neuro.MS  Software as a Service (SaaS) solution (SaaS), which is used in the diagnosis and treatment of patients with multiple sclerosis.

Key Points: 
  • As part of the collaboration, Brainomix will distribute Pixyl's Neuro.MS Software as a Service (SaaS) solution (SaaS), which is used in the diagnosis and treatment of patients with multiple sclerosis.
  • Pixyl's revolutionary deep-learning technology allows radiologists and clinicians to quickly access clinically relevant information for neurological disorders like multiple sclerosis (MS).
  • The CE-marked class IIa product Neuro.MS automatically analyzes brain MRI images to identify, quantify and track abnormalities in under 5 minutes.
  • Brainomix will be distributing Pixyl.Neuro SaaS solution exclusively in the UK and Ireland, the Nordics and key markets across Eastern Europe.

Brainomix announces new partnership with Pixyl to expand its offering with multiple sclerosis solution

Retrieved on: 
Friday, November 25, 2022

OXFORD, England, Nov. 25, 2022 /PRNewswire/ -- Brainomix, an AI-powered medtech solutions company, has announced a new partnership with Pixyl, an award-winning, Grenoble-based medtech specializing in medical neurology imaging. As part of the collaboration, Brainomix will distribute Pixyl's Neuro.MS  Software as a Service (SaaS) solution (SaaS), which is used in the diagnosis and treatment of patients with multiple sclerosis.

Key Points: 
  • As part of the collaboration, Brainomix will distribute Pixyl's Neuro.MS Software as a Service (SaaS) solution (SaaS), which is used in the diagnosis and treatment of patients with multiple sclerosis.
  • Pixyl's revolutionary deep-learning technology allows radiologists and clinicians to quickly access clinically relevant information for neurological disorders like multiple sclerosis (MS).
  • The CE-marked class IIa product Neuro.MS automatically analyzes brain MRI images to identify, quantify and track abnormalities in under 5 minutes.
  • Brainomix will be distributing Pixyl.Neuro SaaS solution exclusively in the UK and Ireland, the Nordics and key markets across Eastern Europe.